| CD20mAbs |
MFC/ Type |
Source |
Regimen
(dose mg/m2) |
Mechanism of action |
Generation |
| Rituximab
(Rituxan, MabThera and Zytux)
Approved in US 1997 |
Biogen, Idec and Genentech
Type I
mAb |
Chimeric |
Rituximab (166 patients with Refractory/ relapsed FL, ORR 48%) [8,77,78]
R-GMCSF (49 Patients with relapsed FL, ORR 74% [79]
R-bendamustine (33 patients with Relapsed FL or MCL, ORR 70%) [80,81]
R-CHOP (63 Untreated patients of DLBCL, ORR 90% ) [82] |
CDC, ADCC, PCD, ADCP |
First |
| Y90 -Ibritumomabtiuxetan (Zevalin)
Approved in US 2002 |
Biogen IDEC Pharmaceuticals Corp
Type I
mAb |
Murine IgG1κ |
Zevalin (54 patients of Rituximab refractory FL, ORR 74%) [83,84]
Zevalinvs Rituximab, randomized multicenter study (143 patients of Relapsed or refractory FL, ORR 80 vs56%) [84,85] |
High CDC
Low ADCC |
| Tositumomab (B1) and I131-Tositumomab (Bexxar)
Approved in US 2003 |
Corixa, Glaxo
Smithkline
Type II
mAb |
Murine IgG2aλ |
Bexxar (250 patients of Relapsed/refractory indolent FL and transformed NHL, ORR 47%-68% repectively) [86]
Bexxar (76 patients of Stage III or IV FL, ORR 95%) [87]
Bexxar +Fludarabine (35 patients of Early stage FL, ORR 98%) [88]
Bexxarvstositumomab (78 patients of Relapsed or refractory NHL, ORR 55% vs19%) [89-91] |
High PCD
Low CDC |
| Reditux
Approved in India 2007 |
Dr. Reddy Laboratories
Type I
mAb |
Murine IgG1 |
Reditux (72 patients of DLBCL, CR 82%) [92] |
Biosimilar |
| Ocrelizumab
(2H7; PRO70769)
Phase III |
Genentech /Roche/ Biogen
Type I
mAb |
Humanized IgG1 |
Ocrelizumab (47 patients of Relapsed/Refractory FL, ORR 38%) 750 [33] |
High ADCC
Low CDC |
Second (Humanized and Fully Human) |
| Veltuzumab (IMMU-106; hA20)
Phase II |
Immunomedics USA
Type I
mAb |
Humanized IgG1κ |
Veltuzumab (82 patients of Relapsed/refractory B-cell NHL) 80-750 [32]
44% ORR in FL
83% ORR in MZL
43% ORR in DLBL |
High CDC |
| Ofatumumab
(2F2; HuMax-CD20; Arzerra)
Approved in US 2009 |
Genmab, Glaxosmithkline
Typr I
mAb |
Fully Human IgG1κ |
OFA, 500-1000 (116 patients of Refractory FL, ORR 13-10%) [93]
OFA-CHOP, 500-1000 (59 patients of Untreated FL, 90-100%) [94]
OFA-FC, 500-1000 (61 patients of Frontline therapy for CLL, 77-73%) [95] |
High CDC
|
| Ocaratuzumab
(AME-D, AME-133)
Phase II |
Mentrik Biotech, Applied molecular evolution
Type I
mAb |
Humanized IgG1(Engineered Fc portion) |
Ocaratuzumab, 100-375 (56 patients of Relapsed/Refractory FL, ORR 36%) [96]
Ocaratuzumab, 375 (50 patients of Relapsed/Refractory FL with low-affinity genotype of FcγRIIIa, ORR 30%) [97] |
High ADCC |
Third (Humanized or fully human with modified Fc region) |
| PRO131921
(RhuMAb; v114)
Phase I/II |
Genentech
Type I
mAb |
Humanized IgG1(Engineered Fc portion) |
PRO131921, 25-800 (24 patients of Relapsed/refractory B cell NHL, ORR 27%) [98] |
High CDC
Low ADCC |
| Obinutuzumab (GA101;Gazyva)
Approved in US Nov 2013 |
Roche
Type II
mAb |
Humanized IgG2κ(Glycoengineered Fc portion) |
GA101, 1600/800- 400/400 (29 patients of Refractory B-cell NHL, ORR 60-35%) [99]
G-CHOP, 1600/800-400/400 (28 patients of Relapsed or refractory FL, ORR 94%)
[100,101]
G-FC, 1600/800-400/400 (28 patients of Relapsed or refractory FL, ORR 93%) [100] |
High PCD&ADCC,
Low CDC |
| Ublituximab
(LFB-R603, EMAB-6)
Phase I |
GTC Bio therapeutics, LFB Biotechnologies
Type I
mAb |
Chimeric; IgG1
Glycoengineered |
Ublituximab, (12 patients of Advanced CLL, ORR 35%) [102] |
High ADCC |
| TRU-015
Phase II |
Trubion Pharmaceuticals Inc., Wyeth
Single chain protein |
SMIL |
37 patients of RA patients [74] |
High ADCC
Low CDC |
